Dalriada Drug Discovery announced a strategic collaboration with atai Life Sciences' N.V. newly launched platform company Invyxis, focused on developing next-generation small molecule therapies based on psychedelics and related compounds for mental health disorders. The goal of the partnership is to establish a diversified pipeline of new chemical entities (NCE) designed to improve upon current compounds in clinical and preclinical development to treat these disorders. Initial work will focus on designing novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets to follow.

In addition to the creation of the pipeline, the collaboration critically includes the creation of a substantial pharmacology platform that will enable deep interrogation of known and novel compounds at a target level. There is a significant opportunity for improved next-generation therapies to address mental health disorders. Over the past several years, a massive amount of preclinical and clinical knowledge has been generated around the use of psychedelic and related compounds for the treatment of these disorders.

Investing in rapidly advancing NCE programs in this emerging and rapidly evolving space is a critical opportunity. As part of the collaboration, Dalriada assumes responsibility for the discovery R&D programs, including the hit identification, hit to lead, and lead optimization stages up to the nomination of the development candidate. atai will be responsible for the preclinical and clinical development.